Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 4/20 | 0.42 |
| ▸ | DAO | P14920 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CA3 | P07451 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.32 |
| ▸ | USP8 | P40818 | 1/20 | 0.31 |
| ▸ | USP7 | Q93009 | 1/20 | 0.31 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31633778 | 0.87 | ACHE (0.41) | ACHEDAONFE2L2RAPGEF4TSHR | |
| SCHEMBL3475177 | 0.87 | ACHE (0.41) | ACHEDAONFE2L2RAPGEF4TSHR | |
| SCHEMBL172114 | 0.82 | ACHE (0.36) | ACHEDAONFE2L2 | |
| SCHEMBL3410281 | 0.82 | ACHE (0.32) | ACHEDAO | |
| SCHEMBL15497514 | 0.82 | ALDH1A1 (0.37) | ACHEDAORAPGEF4ALDH1A1 | |
| SCHEMBL19944381 | 0.82 | TRPA1 (0.40) | ACHEDAOTDP1CA3CA6 | |
| SCHEMBL5241664 | 0.82 | CYP3A4 (0.46) | ACHEDAOTDP1CA6CA5A | |
| SCHEMBL11321094 | 0.82 | DAO (0.34) | ACHEDAOUSP8USP7 | |
| SCHEMBL2329832 | 0.82 | ALDH1A1 (0.32) | ACHEDAOALDH1A1 | |
| SCHEMBL14866234 | 0.78 | LMNA (0.37) | CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528773-B2 | Non-lysosomal glucosylceramidase inhibitors and uses thereof | ALECTOS THERAPEUTICS INC. (CA) | 2026-01-20 | — | — | US | disclosed |
| US-12374722-B2 | Electrolytes for lithium batteries | SION POWER CORPORATION (US) | 2025-07-29 | — | — | US | disclosed |
| US-11916180-B2 | Organic solar cell and photodetector materials and devices | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-02-27 | — | — | US | disclosed |
| US-11916180-B2 | Organic solar cell and photodetector materials and devices | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230348387-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2023-11-02 | — | — | US | disclosed |
| EP-4229707-A1 | ELECTROLYTES FOR LITHIUM BATTERIES | SION POWER CORPORATION (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20230263056-A1 | ORGANIC SOLAR CELL AND PHOTODETECTOR MATERIALS AND DEVICES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-17 | — | — | US | disclosed |
| CN-116491008-A | Electrolyte for lithium battery | 赛昂能源有限公司 | 2023-07-25 | — | — | CN | disclosed |
| US-20230227437-A1 | IMMUNOMODULATOR | HITGEN INC (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20230227437-A1 | IMMUNOMODULATOR | HITGEN INC (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20080058521-A1 | Processes for the preparation of compounds | WYETH (US) | 2008-03-06 | — | — | US | disclosed |
| EP-1877379-A1 | HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90 | Astex Therapeutics Limited (GB) | 2008-01-16 | — | — | EP | disclosed |
| US-20070276026-A1 | Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-29 | — | — | US | disclosed |
| US-20070276026-A1 | Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-29 | — | — | US | disclosed |
| US-20070276026-A1 | Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-29 | — | — | US | disclosed |
| US-20070259886-A1 | (2,4-Dihydroxy-5-isopropyl-phenyl)-[5-(2-dimethylamino-ethoxy)-1,3-dihydro-isoindol-2-yl]-methanone; inhibits or modulates activity of heat shock protein Hsp90; useful for treating cancer, particularly hematopoietic tumors of lymphoid or myeloid lineage, prostate, lung, breast cancer, melanoma | ASTEX THERAPEUTICS, LTD. (GB) | 2007-11-08 | — | — | US | disclosed |
| US-20070259871-A1 | Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-08 | — | — | US | disclosed |
| US-20070259871-A1 | Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-08 | — | — | US | disclosed |
| US-20070259871-A1 | Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-08 | — | — | US | disclosed |
| WO-2006109085-A1 | HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90 | ASTEX THERAPEUTICS LIMITED (GB) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348387-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | GBA1, GBA2, GAA | ACHE 1391/4885DAO 769/4885NFE2L2 4606/4885 |
| US-20070276026-A1 | Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 | HSP90AB1, HSP90AB2P, HSP90AA1 | ACHE 4762/4885DAO 1142/4885NFE2L2 507/4885 |
| US-12528773-B2 | Non-lysosomal glucosylceramidase inhibitors and uses thereof | GBA1, GBA2, GAA | ACHE 2216/4885DAO 304/4885NFE2L2 3474/4885 |
| US-20070259886-A1 | (2,4-Dihydroxy-5-isopropyl-phenyl)-[5-(2-dimethylamino-ethoxy)-1,3-dihydro-isoindol-2-yl]-methanone; inhibits or modulates activity of heat shock protein Hsp90; useful for treating cancer, particularly hematopoietic tumors of lymphoid or myeloid lineage, prostate, lung, breast cancer, melanoma | HSP90AB2P, HSP90AA1, HSP90AB1 | ACHE 4869/4885DAO 4134/4885NFE2L2 744/4885 |
| US-20080058521-A1 | Processes for the preparation of compounds | MKI67, MCL1, DCX | ACHE 2596/4885DAO 2411/4885NFE2L2 485/4885 |
| US-20230227437-A1 | IMMUNOMODULATOR | IL17A, IL2, IL2RA | ACHE 4158/4885DAO 2378/4885NFE2L2 637/4885 |
| US-20230263056-A1 | ORGANIC SOLAR CELL AND PHOTODETECTOR MATERIALS AND DEVICES | OCIAD1, OCIAD2, CDH1 | ACHE 4455/4885DAO 1469/4885NFE2L2 142/4885 |
| US-20070259871-A1 | Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 | HSP90AB1, HSP90AB2P, HSP90AA1 | ACHE 4763/4885DAO 1140/4885NFE2L2 515/4885 |
| US-11916180-B2 | Organic solar cell and photodetector materials and devices | OCIAD1, OCIAD2, CDH1 | ACHE 4455/4885DAO 1469/4885NFE2L2 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.